Abbott launches 3-minute, in-office A1c blood test for diagnosing diabetes

abbott
The test improves upon Abbott's previous Afinion HbA1c assay, which the FDA approved solely for monitoring long-term glycemic control at the point of care. (Image: Abbott)

Abbott has launched its new point-of-care diabetes blood test that can provide hemoglobin A1c results in only three minutes, allowing clinicians to develop and start care plans within a patient’s single visit to a doctor’s office.

The company describes the assay as the first and only rapid test cleared by the FDA for use in diagnosing diabetes or for monitoring a person’s risk for developing the condition in the future. The Afinion HbA1c Dx test is now available for use on Abbott’s Afinion 2 and AS100 analyzers.

"In addition to giving physicians the certainty of diagnosis they need to make informed decisions during a patient visit, the HbA1c Dx assay gives people living with diabetes near real-time results, so that in consultation with their doctor they can make adjustments to their lifestyle and better manage their condition,” Elizabeth Balthrop, vice president of cardiometabolic and informatics in Abbott’s Rapid Diagnostics diagnostics, said in a statement.

Sponsored by Clinical Ink

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Ink’s intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

RELATED: ADA: Real-world data show lower A1c levels with Abbott's FreeStyle Libre CGM in Type 2 diabetes

The diagnostics assay first received FDA clearance on the AS100 analyzer in May 2018, around the same time as the launch of the Afinion 2 platform. The new test also complements the previous Afinion HbA1c assay, which was approved solely for monitoring long-term glycemic control at the point-of-care, the company said.

RELATED: Abbott notches FDA nod for first fingerprick-free CGM

Earlier this month at the annual Scientific Sessions of the American Diabetes Association, Abbott presented its first evaluation of real-world data for its FreeStyle Libre continuous glucose monitoring system in people with Type 2 diabetes.

The data showed that the system could help reduce hemoglobin A1c levels by nearly a full percentage point after three months of use among patients who had taken multiple insulin injections per day for several years.

Suggested Articles

The FDA cleared a miniaturized and disposable sensor patch designed to detect early complications from IV drug infusions.

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Philips announced plans to integrate BioIntelliSense’s health-tracking sticker into its remote patient monitoring programs.